Abstract
Inflammation plays a fundamental role in many chronic diseases, including atherosclerosis associated cardiovascular disease. Adhesion of immune cells plays a critical role in the inflammatory response and indeed the pathophysiology of inflammatory related diseases. P-selectin is an inflammatory adhesion molecule, enabling the recruitment of leukocytes to the endothelium and to activated platelets involved in the growing thrombus. P-selectin is critical in the progression of atherosclerosis as evidenced by knockout animal models where P-selectin knockout mice crossed with apoE deficient mice exhibit significantly reduced atherosclerosis and leukocyte recruitment in the plaque. A soluble form of P-selectin also exists, which may have pro-atherogenic and pro-thrombotic effects. Thus targeting of P- selectin remains a strong clinical candidate for developing novel therapeutic strategies in inflammatory diseases. This review will discuss the role of P-selectin and describe the function of P-selectin antagonists as clinical targets.
Keywords: P-selectin, inflammation, atherosclerosis, leukocyte, endothelium, cellular adhesion
Current Pharmaceutical Design
Title: P-Selectin Antagonism in Inflammatory Disease
Volume: 16 Issue: 37
Author(s): Kevin J. Woollard and Jaye Chin-Dusting
Affiliation:
- Baker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Rd Central, Melbourne VIC 8008, Australia.,Australia
Keywords: P-selectin, inflammation, atherosclerosis, leukocyte, endothelium, cellular adhesion
Abstract: Inflammation plays a fundamental role in many chronic diseases, including atherosclerosis associated cardiovascular disease. Adhesion of immune cells plays a critical role in the inflammatory response and indeed the pathophysiology of inflammatory related diseases. P-selectin is an inflammatory adhesion molecule, enabling the recruitment of leukocytes to the endothelium and to activated platelets involved in the growing thrombus. P-selectin is critical in the progression of atherosclerosis as evidenced by knockout animal models where P-selectin knockout mice crossed with apoE deficient mice exhibit significantly reduced atherosclerosis and leukocyte recruitment in the plaque. A soluble form of P-selectin also exists, which may have pro-atherogenic and pro-thrombotic effects. Thus targeting of P- selectin remains a strong clinical candidate for developing novel therapeutic strategies in inflammatory diseases. This review will discuss the role of P-selectin and describe the function of P-selectin antagonists as clinical targets.
Export Options
About this article
Cite this article as:
J. Woollard Kevin and Chin-Dusting Jaye, P-Selectin Antagonism in Inflammatory Disease, Current Pharmaceutical Design 2010; 16(37) . https://dx.doi.org/10.2174/138161210794519192
DOI https://dx.doi.org/10.2174/138161210794519192 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Vulnerable Plaque and Inflammation: Potential Clinical Strategies
Current Pharmaceutical Design Roles of Arterial Baroreceptor Reflex During Bezold-Jarisch Reflex
Current Cardiology Reviews Why are People with “Poor Lung Function” At Increased Atherothrombotic Risk?A Critical Review with Potential Therapeutic Indications
Current Vascular Pharmacology Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Induction of Myocardial Fibrosis and Hypertrophy by Natriuretic Peptides
Vascular Disease Prevention (Discontinued) Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Inhibition of Human Serine Racemase, an Emerging Target for Medicinal Chemistry
Current Drug Targets The Role of the Endothelium in Premature Atherosclerosis: Molecular Mechanisms
Current Medicinal Chemistry Ozone: A Multifaceted Molecule with Unexpected Therapeutic Activity
Current Medicinal Chemistry A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Current Diagnostic Modalities for Vulnerable Plaque Detection
Current Pharmaceutical Design Heart Transplantation in Biventricular Congenital Heart Disease: Indications, Techniques, and Outcomes
Current Cardiology Reviews Does Erythropoietin Always Win?
Current Medicinal Chemistry Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Disruption of Circadian Rhythms and Delirium, Sleep Impairment and Sepsis in Critically ill Patients. Potential Therapeutic Implications for Increased Light-Dark Contrast and Melatonin Therapy in an ICU Environment
Current Pharmaceutical Design Lipoproteins, Stroke and Statins
Current Vascular Pharmacology CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Central Arterial Aging and Angiotensin II Signaling
Current Hypertension Reviews Glutathione Peroxidase: A Potential Marker for the Most Common Diseases and Disorders
Recent Patents on Biomarkers